Reviewer's report

Title: A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine

Version: 1 Date: 3 March 2015

Reviewer: I-Fen Chen

Reviewer's report:

This study report a rare case of concurrent BDC and RCC, who was treated by sunitinib and gemcitabine. Indeed, this kind of patient is extremely rare. Any successful treatment could give us a new clue to further management.

But there were several concerns about this study which need major compulsory revisions

1. The treatment was only 13 days of sunitinib treatment and two doses of gemcitabine. It's quite different from common clinical practices. Clinically, we usually need about 2 - 3 months' treatment to evaluate the response.

2. The CT scan for lung metastasis showed a tumor became smaller, but the other tumor seems unchanged. It's hard to conclude a "partial response" by RECIST criteria.

3. The SNP study didn't show any predictive value for sunitinib treatment efficacy.

So there is little value in contribution to current medical knowledge or a change in clinical practice.

Level of interest: An article of insufficient interest to warrant publication in a scientific/medical journal

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.